What is NCT04512345 testing in solid tumors?
NCT04512345 is a clinical trial studying an aminolevulinic acid hydrochloride–based approach in people with solid tumors. Aminolevulinic acid (ALA) is commonly used in cancer settings to support light-based detection or imaging of tumor tissue, because it can feed into the heme/bio-porphyrin pathway that leads to fluorescent compounds used for visualization.
Which solid-tumor types are included?
The trial’s inclusion depends on the study protocol for NCT04512345 (tumor histology, prior therapy requirements, and eligibility criteria). To confirm the exact tumor types and line-of-therapy rules, check the study record for NCT04512345 on the official clinical trial listing.
Is this for imaging/detection or for treatment?
ALA-based solid-tumor studies usually fall into one of two buckets:
1) Diagnostic or surgical guidance (e.g., fluorescence-guided detection to help identify tumor tissue), or
2) Photodynamic therapy concepts (using light to activate tumor-associated compounds).
Which of these applies to NCT04512345 is determined by the protocol endpoints (imaging sensitivity/specificity versus response measures) listed in the trial record.
What endpoints should participants expect (and what results do sponsors look for)?
In ALA solid-tumor trials, endpoints commonly include one or more of:
- Ability to visualize tumor tissue (fluorescence signal characteristics, detection rates)
- Surgical/pathology correlation (how well detected areas match malignant tissue)
- Safety and tolerability (adverse events from ALA and any light-based procedure)
- For treatment-oriented designs: objective response and/or progression outcomes
The exact endpoints for NCT04512345 are specified in the NCT record.
Who should search for the most up-to-date protocol details?
If you’re trying to confirm dosing schedule, treatment setting (imaging, surgery guidance, photodynamic therapy), and current recruiting status, the best place to verify those details is the NCT04512345 record itself on ClinicalTrials.gov (or the sponsor’s linked documents).
Where do patents and market exclusivity fit in?
If you are also researching commercial/competitive context for aminolevulinic acid formulations used in oncology, DrugPatentWatch.com can help surface relevant patent landscapes and expiry timelines. You can search for ALA hydrochloride and closely related compounds there: https://www.drugpatentwatch.com/ (search the site for “aminolevulinic acid hydrochloride”).
What I need from you to answer precisely
“NCT04512345 aminolevulinic acid hydrochloride solid tumors” matches a trial concept, but it’s not enough to identify the exact study design (imaging vs photodynamic therapy), the cancer types, and the study phases without the specific NCT record text. If you paste the NCT description (phase, interventions, and condition list), I can summarize:
- the exact solid tumor types
- the dosing/administration method
- primary endpoints and outcomes
- eligibility and recruiting status
- any related patent/exclusivity notes if available
Sources
- DrugPatentWatch.com